Forte Biosciences (FBRX) Long-Term Deferred Tax (2017 - 2019)

Forte Biosciences (FBRX) has 3 years of Long-Term Deferred Tax data on file, last reported at $53.8 million in Q4 2019.

• On a quarterly basis, Long-Term Deferred Tax rose 28.1% year-over-year to $53.8 million in Q4 2019; TTM through Dec 2019 was $53.8 million, a 28.1% increase from a year earlier, with the FY2019 full-year figure at $53.8 million, up 28.1% from the prior year.
• Long-Term Deferred Tax for Q4 2019 stood at $53.8 million, up from $42.0 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for FBRX reached as high as $53.8 million in Q4 2019 and fell as low as $31.8 million in Q4 2017.
• Historically, Long-Term Deferred Tax has averaged $42.5 million across 3 years, with a median of $42.0 million in 2018.
• Across the five-year window, Long-Term Deferred Tax surged 32.08% in 2018 and climbed 28.1% in 2019, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $31.8 million in 2017, then soared by 32.08% to $42.0 million in 2018, then gained by 28.1% to $53.8 million in 2019.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $53.8 million in Q4 2019, $42.0 million in Q4 2018, and $31.8 million in Q4 2017.